Evolent Health, Inc. (NYSE:EVH) Receives Consensus Recommendation of “Buy” from Brokerages

Evolent Health, Inc. (NYSE:EVH) has been assigned a consensus recommendation of “Buy” from the thirteen ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $18.38.

A number of analysts recently issued reports on EVH shares. JMP Securities dropped their price objective on Evolent Health from $27.00 to $18.00 and set a “market outperform” rating on the stock in a report on Friday, January 10th. UBS Group decreased their target price on Evolent Health from $27.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, January 16th. Canaccord Genuity Group decreased their target price on Evolent Health from $23.00 to $16.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Royal Bank of Canada decreased their target price on Evolent Health from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 14th. Finally, Stephens decreased their target price on Evolent Health from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Tuesday, January 21st.

Hedge Funds Weigh In On Evolent Health

Institutional investors have recently modified their holdings of the company. Creative Planning grew its position in Evolent Health by 12.2% during the 2nd quarter. Creative Planning now owns 18,091 shares of the technology company’s stock worth $346,000 after acquiring an additional 1,973 shares during the last quarter. GAMMA Investing LLC grew its position in Evolent Health by 5,365.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock worth $45,000 after acquiring an additional 1,556 shares during the last quarter. Friedenthal Financial bought a new position in Evolent Health during the 3rd quarter worth approximately $723,000. Moody Aldrich Partners LLC bought a new position in Evolent Health during the 3rd quarter worth approximately $1,421,000. Finally, Values First Advisors Inc. grew its position in Evolent Health by 21.0% during the 3rd quarter. Values First Advisors Inc. now owns 32,129 shares of the technology company’s stock worth $909,000 after acquiring an additional 5,583 shares during the last quarter.

Evolent Health Stock Performance

Shares of EVH opened at $9.96 on Friday. The stock’s 50-day simple moving average is $10.88 and its 200 day simple moving average is $19.37. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of -10.94 and a beta of 1.45. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. Evolent Health has a 52-week low of $9.45 and a 52-week high of $35.00.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.